These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11989931)

  • 1. Is there an advantage for oral therapy in elderly? UFT.
    Labianca R; Beretta G; Mosconi S; Pessi MA
    Tumori; 2002; 88(1 Suppl 1):S71-2. PubMed ID: 11989931
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
    Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
    Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).
    Nishina T; Moriwaki T; Shimada M; Higashijima J; Sakai Y; Masuishi T; Ozeki M; Amagai K; Negoro Y; Indo S; Denda T; Sato M; Yamamoto Y; Nakajima G; Mizuta M; Takahashi I; Hiroshima Y; Ishida H; Maeba T; Hyodo I
    Clin Colorectal Cancer; 2016 Sep; 15(3):236-42. PubMed ID: 26778644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan.
    Hsu TC; Wang CC
    J Comp Eff Res; 2019 Jan; 8(2):73-79. PubMed ID: 30560687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
    Damle B; Ravandi F; Kaul S; Sonnichsen D; Ferreira I; Brooks D; Stewart D; Alberts D; Pazdur R
    Clin Cancer Res; 2001 Mar; 7(3):517-23. PubMed ID: 11297242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
    Etienne-Grimaldi MC; François E; Cardot JM; Renée N; Douillard JY; Gamelin E; Bennouna J; Château Y; Milano G
    Clin Pharmacokinet; 2007; 46(11):953-63. PubMed ID: 17922560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience.
    González Barón M; Feliu J; Garcia Girón C; Espinosa J; Martinez B; Blanco E; Crespo MC; Ordóñez A; Espinosa E; de Castro J; Juárez F; Colmenarejo A
    Oncology; 1997; 54 Suppl 1():24-9. PubMed ID: 8978581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
    Mizushima T; Tamagawa H; Matsuda C; Murata K; Fukunaga M; Ota H; Hasegawa J; Tsujie M; Fukuzaki T; Hata T; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Oncology; 2015; 89(3):152-8. PubMed ID: 25967649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
    Alliot C
    Br J Cancer; 2004 Aug; 91(3):599-600; author reply 599-601. PubMed ID: 15238988
    [No Abstract]   [Full Text] [Related]  

  • 10. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
    Petrioli R; Sabatino M; Fiaschi AI; Marsili S; Pozzessere D; Messinese S; Correale P; Civitelli S; Tanzini G; Tani F; De Martino A; Marzocca G; Lorenzi M; Giorgi G; Francini G
    Br J Cancer; 2004 Jan; 90(2):306-9. PubMed ID: 14735168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
    Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P
    Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinoma.
    Hoff PM; Pazdur R
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):48-50. PubMed ID: 10442361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients].
    Mizushima T; Mizuno H; Ito T; Hoki M; Souma Y; Iwamoto T; Ozawa H; Kanou T; Nakamori Y; Iwase K
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):941-4. PubMed ID: 16835484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
    Sadahiro S; Suzuki T; Tanaka A; Okada K; Nagase H; Uchida J
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):285-91. PubMed ID: 22752215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer.
    Shibahara K; Yamamoto M; Kakeji Y; Sakata H; Maehara Y
    Anticancer Res; 2008; 28(3B):1779-83. PubMed ID: 18630459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
    Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
    J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival benefit of oral tegafur/uracil and leucovorin as a first line therapy for elderly patients with advanced or metastatic colorectal cancer.
    Murata K; Yamamoto H; Fukunaga M; Kato T; Ohnishi T; Uemura Y; Ohta H; Kimura F; Ohue M; Nezu R; Sekimoto M; Ikeda M; Mizushimaz T; Doki Y; Mori M;
    Hepatogastroenterology; 2014; 61(129):94-8. PubMed ID: 24895801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a low-fat meal on the oral bioavailability of UFT and leucovorin in patients with colorectal cancer.
    Furuhata T; Meguro M; Nishidate T; Okita K; Ishiyama G; Iwayama Y; Hosokawa Y; Tsuruma T; Kimura Y; Mizuguchi T; Sasaki K
    Int J Clin Oncol; 2009 Dec; 14(6):529-33. PubMed ID: 19967490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.